Commercial investment comprises the majority of funding in the psychedelic sector, with nearly all investment going to drug discovery over the last two years. Meanwhile, many projects outside of the scope of commercial markets require financial support. By committing strategic funds and financial gifts to mission-driven businesses, drug policy reform, public health education, harm reduction, and diversity and inclusion initiatives, philanthropists and investors have an opportunity to shape the field. In this session, we will explore how constructive capital can build equity and social value in the burgeoning psychedelic economy.